Figures and Tables

From the following article:

Antibody-targeted radiation cancer therapy

Diane E. Milenic, Erik D. Brady & Martin W. Brechbiel

Nature Reviews Drug Discovery 3, 488-499 (June 2004)

doi:10.1038/nrd1413

Figure 1 - Antibody-targeted radiation cancer therapy

Figure 1

A monoclonal antibody linked to a radionuclide.

Figure 2 - Antibody-targeted radiation cancer therapy

Figure 2

A representation of the periodic table, highlighting those elements that are of interest for nuclear medicine and radiation oncology applications.

Figure 3 - Antibody-targeted radiation cancer therapy

Figure 3

Comparison of path lengths and emission tracks of alpha- and beta--particle emissions used in antibody-targeted radiation therapy.

Figure 4 - Antibody-targeted radiation cancer therapy

Figure 4

A general view of the conjugation of a bifunctional chelating agent to a monoclonal antibody.

Figure 5 - Antibody-targeted radiation cancer therapy

Figure 5

Selected examples of bifunctional chelating agents that have been or are currently in antibody-targeted radiation therapy clinical trials.

Table 1 - Antibody-targeted radiation cancer therapy

Table 1

Representative monoclonal antibodies in advanced radioimmunotherapy clinical trials

Table 2 - Antibody-targeted radiation cancer therapy

Table 2

Therapeutic radionuclides